Gritstone bio, Inc. (GRTS)

Gritstone bio, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and infectious diseases. Their pipeline includes neoantigen-based and off-the-shelf immunotherapies, as well as vaccines against SARS-CoV-2 and HIV.

46/100 AI Score MCap $3.80M Vol 55.25M

Company Overview

CEOAndrew R. Allen BCh, BM, MA, MRCP,
Employees231
HeadquartersEmeryVille, CA, US
IPO Year2018

Gritstone bio is pioneering the next generation of cancer and infectious disease immunotherapies, leveraging its innovative vaccine platform to target neoantigens and deliver personalized treatments, positioning it for significant growth in the rapidly evolving biotechnology landscape and strategic collaborations.

Investment Thesis

Investing in Gritstone bio presents a compelling opportunity due to its innovative immunotherapy platforms and diversified pipeline targeting significant unmet medical needs in oncology and infectious diseases. The GRANITE and SLATE programs hold promise in the treatment of solid tumors, while the CORAL vaccine platform offers potential in addressing current and future SARS-CoV-2 variants. The company's strategic collaborations with bluebird bio, Gilead Sciences, and Genevant Sciences further validate its technology and provide financial resources for development. While the company's Profit Margin is currently -10405.0% and Gross Margin is -470.3%, these figures are typical for clinical-stage biotech companies that are heavily investing in R&D. Key catalysts include upcoming clinical trial results for GRANITE and SLATE, as well as potential partnerships for the CORAL vaccine platform. Success in these areas could drive significant value appreciation for GRTS.

Key Highlights

  • Gritstone bio is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases.
  • Lead product candidate GRANITE is a neoantigen-based immunotherapy targeting solid tumors, including lung, gastroesophageal, bladder, and colorectal cancers.
  • Developing SLATE, an off-the-shelf immunotherapy candidate for common solid tumors, offering broader patient applicability.
  • CORAL, a SARS-CoV-2 vaccine platform, aims to provide protection against current and future variants.
  • Strategic collaborations with bluebird bio, Gilead Sciences, and Genevant Sciences validate technology and provide financial support.

Competitors

Strengths

  • Innovative neoantigen-based immunotherapy platform.
  • Diversified pipeline targeting cancer and infectious diseases.
  • Strategic collaborations with established pharmaceutical companies.
  • Experienced management team with expertise in immunotherapy development.

Weaknesses

  • Clinical-stage company with no currently approved products.
  • High R&D expenses and negative profit margins.
  • Dependence on clinical trial success and regulatory approvals.
  • Limited commercialization capabilities.

Catalysts

  • Upcoming: Clinical trial results for GRANITE in metastatic non-small cell lung cancer.
  • Upcoming: Clinical trial results for SLATE in colorectal cancer.
  • Ongoing: Potential partnerships for CORAL vaccine platform.
  • Ongoing: Advancement of HIV therapeutic vaccine candidate into clinical trials.

Risks

  • Potential: Clinical trial failures or delays.
  • Potential: Regulatory setbacks or rejection of product candidates.
  • Ongoing: Competition from other biotechnology and pharmaceutical companies.
  • Ongoing: Dependence on securing additional funding to support R&D activities.
  • Potential: Intellectual property disputes or challenges.

Growth Opportunities

  • Expansion of GRANITE clinical trials: Gritstone has the opportunity to expand the clinical trials for GRANITE to include additional solid tumor types and combination therapies. The market for solid tumor treatments is substantial, with a global market size estimated at billions of dollars annually. Positive clinical data from these expanded trials could lead to accelerated regulatory approval and commercialization, driving significant revenue growth for Gritstone.
  • Advancement of SLATE program: The SLATE program, an off-the-shelf immunotherapy candidate, offers the potential to treat a broader range of patients with common solid tumors. Successful clinical development and commercialization of SLATE could tap into a large market, providing a significant growth opportunity for Gritstone. The timeline for this growth opportunity is dependent on clinical trial progress, with potential for commercialization within the next 3-5 years.
  • Partnerships for CORAL vaccine platform: Gritstone's CORAL vaccine platform, designed to address SARS-CoV-2 variants, presents a valuable opportunity for partnerships with larger pharmaceutical companies. The global market for COVID-19 vaccines remains significant, and Gritstone's platform could offer a differentiated approach to addressing emerging variants. Securing a partnership could provide substantial upfront payments, milestone payments, and royalties, driving revenue growth.
  • Development of HIV therapeutic vaccine: Gritstone is developing a therapeutic vaccine candidate targeting HIV infection, a disease with a significant unmet medical need. Successful development and commercialization of this vaccine could address a large patient population and generate substantial revenue. The timeline for this growth opportunity is longer-term, dependent on clinical trial progress and regulatory approval.
  • Expansion of neoantigen discovery platform: Gritstone's neoantigen discovery platform is a key competitive advantage, enabling the identification of novel targets for immunotherapy. Expanding the capabilities of this platform and applying it to new disease areas could lead to the development of additional product candidates and partnerships, driving long-term growth for the company.

Opportunities

  • Expansion of clinical trials to new indications.
  • Partnerships for commercialization of product candidates.
  • Advancements in personalized medicine and immunotherapy.
  • Growing market for cancer and infectious disease therapies.

Threats

  • Clinical trial failures and regulatory setbacks.
  • Competition from established pharmaceutical companies.
  • Changes in the regulatory landscape.
  • Economic downturn and reduced healthcare spending.

Competitive Advantages

  • Proprietary neoantigen discovery platform.
  • Personalized immunotherapy approach.
  • Off-the-shelf immunotherapy candidates.
  • Strategic collaborations with leading pharmaceutical companies.

About

Gritstone bio, Inc., founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company dedicated to developing cutting-edge immunotherapies. The company's mission is to combat cancer and infectious diseases through innovative vaccine platforms that stimulate the body's immune system. Gritstone's lead product candidate, GRANITE, is a neoantigen-based immunotherapy designed to treat solid tumors, including metastatic non-small cell lung cancer, gastroesophageal, bladder, and microsatellite stable colorectal cancers. This personalized approach targets the unique mutations present in each patient's tumor, aiming for a more effective and durable response. In addition to GRANITE, Gritstone is developing SLATE, an off-the-shelf immunotherapy candidate targeting common solid tumors like metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. This off-the-shelf approach offers a broader application, potentially benefiting a larger patient population. Furthermore, Gritstone is leveraging its platform to address infectious diseases, with CORAL, a SARS-CoV-2 vaccine platform, designed to deliver spike and additional SARS-CoV-2 T cell epitopes for enhanced protection against variants. The company is also developing a therapeutic vaccine candidate targeting HIV infection, aiming to treat and potentially cure the disease. Gritstone has established strategic collaborations with companies like bluebird bio, Inc., Gilead Sciences, Inc., and Genevant Sciences GmbH, further validating its technology and expanding its development capabilities. Formerly known as Gritstone Oncology, Inc., the company rebranded to Gritstone bio, Inc. in May 2021 to reflect its broader focus on both cancer and infectious diseases.

What They Do

  • Develop neoantigen-based immunotherapies for solid tumors.
  • Create off-the-shelf immunotherapies for common cancers.
  • Design vaccines against SARS-CoV-2 variants.
  • Develop therapeutic vaccines for HIV infection.
  • Utilize a proprietary neoantigen discovery platform.
  • Partner with pharmaceutical companies for development and commercialization.

Business Model

  • Develop and out-license immunotherapies and vaccines.
  • Generate revenue through strategic collaborations and partnerships.
  • Receive upfront payments, milestone payments, and royalties from partners.
  • Potentially commercialize products independently upon regulatory approval.

Industry Context

The biotechnology industry is characterized by rapid innovation and intense competition, with companies vying to develop novel therapies for unmet medical needs. The immunotherapy market, in particular, is experiencing significant growth, driven by advancements in personalized medicine and the increasing prevalence of cancer and infectious diseases. Gritstone bio is positioned within this landscape as a developer of neoantigen-based immunotherapies, a promising approach that leverages the unique mutations present in individual tumors. Competitors like Affimed (AFMD), Aptose Biosciences (APTO), BioCellebrate (BCEL), Gamida Cell (GMDA), and Idera Pharmaceuticals (IDRA) are also pursuing innovative approaches in oncology and immunology, but Gritstone's focus on neoantigen-based therapies and its diversified pipeline differentiate it within the competitive landscape.

Key Customers

  • Patients with solid tumors (e.g., lung, colorectal, pancreatic cancer).
  • Individuals at risk of SARS-CoV-2 infection.
  • People living with HIV.
  • Pharmaceutical companies seeking innovative immunotherapy technologies.
AI Confidence: 70% Updated: 2/8/2026

Financials

Chart & Info

Price Chart

Gritstone bio, Inc. (GRTS) stock price: $0.03 (+0.00, +0.00%)

Why Bull

  • •Gritstone's recent insider buying suggests strong confidence from management in the company's future prospects.
  • •Community sentiment has shifted positively, with discussions highlighting innovative vaccine development that could position Gritstone as a leader in immunotherapy.
  • •Recent collaborations with major pharmaceutical companies have generated optimism about potential breakthroughs and increased visibility in the market.
  • •Positive news flow regarding clinical trial advancements has bolstered investor interest, indicating growing belief in the company's pipeline.

Why Bear

  • •Concerns over the competitive landscape in the biotech sector may weigh on Gritstone, as larger firms ramp up similar research efforts.
  • •Recent social media discussions revealed skepticism about the pace of clinical trial results, with some investors questioning the timeline for product commercialization.
  • •Insider selling activity, although not significant, has raised eyebrows among investors, potentially signaling a lack of confidence in short-term performance.
  • •Market perception remains cautious due to the volatility typically associated with biotech stocks, which may deter risk-averse investors.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for GRTS including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Gritstone bio, Inc. (GRTS) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for GRTS.

Make a Prediction

Set your price target for Gritstone bio, Inc. (GRTS), choose a timeframe, and track your prediction accuracy.

Current price: $0.03

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRTS.

Price Targets

Wall Street price target analysis for GRTS.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates GRTS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Gritstone bio, Inc. do?

Gritstone bio, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary neoantigen discovery platform to identify unique targets for personalized cancer treatments. Its lead product candidate, GRANITE, is a neoantigen-based immunotherapy designed to treat solid tumors. Gritstone is also developing SLATE, an off-the-shelf immunotherapy, and CORAL, a SARS-CoV-2 vaccine platform, demonstrating its commitment to addressing significant unmet medical needs through cutting-edge science and strategic partnerships.

Is GRTS stock a good buy?

GRTS stock represents a high-risk, high-reward investment opportunity. As a clinical-stage biotech company, Gritstone's value is heavily dependent on the success of its clinical trials and regulatory approvals. While the company's innovative immunotherapy platforms and diversified pipeline offer significant potential, investors should be aware of the inherent risks associated with drug development. The company's negative Profit Margin of -10405.0% reflects its current stage of development. Positive clinical trial data and strategic partnerships could drive significant value appreciation, but negative results could have a detrimental impact on the stock price. A balanced approach considering both the potential upside and the inherent risks is crucial.

What are the main risks for GRTS?

The primary risks for Gritstone bio include clinical trial failures, regulatory setbacks, and competition from other biotechnology and pharmaceutical companies. As a clinical-stage company, Gritstone is heavily reliant on the success of its clinical trials, and any negative results could significantly impact its stock price. Regulatory approval is also a major hurdle, and delays or rejections could derail the company's development plans. Furthermore, the biotechnology industry is highly competitive, and Gritstone faces competition from larger, more established companies with greater resources. The company's ongoing need for funding to support R&D activities also poses a risk, as it may need to raise additional capital through dilutive financing.

Is GRTS a good stock to buy?

Whether GRTS is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the GRTS MoonshotScore?

The MoonshotScore for GRTS is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is GRTS data updated?

GRTS stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to GRTS is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for GRTS?

Growth catalysts for Gritstone bio, Inc. (GRTS) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Gritstone bio, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are GRTS's main competitors?

Gritstone bio, Inc. (GRTS) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether GRTS has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about GRTS?

Wall Street analyst coverage for GRTS includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is GRTS's market cap?

Market capitalization (market cap) for GRTS is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows GRTS's current market cap alongside enterprise value and other valuation metrics.

How has GRTS stock performed recently?

GRTS's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing GRTS's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in GRTS?

Key risk categories for GRTS include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures GRTS's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling GRTS?

Insider trading activity for GRTS tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is GRTS a good stock for beginners?

Gritstone bio, Inc. (GRTS) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is GRTS for first-time investors?

Every stock carries risk, including Gritstone bio, Inc. (GRTS). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like GRTS.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Stock data pending update.
  • Financial metrics based on available data and may not reflect the most recent information.
Data Sources
profilefundamentalsexistingCopy